{"id":"ksl-w","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"KSL-W works by inhibiting the PD-1/PD-L1 interaction, which is involved in the regulation of the immune response. This inhibition can lead to the activation of T cells and the enhancement of anti-tumor immunity.","oneSentence":"KSL-W is a small molecule drug that targets the PD-1/PD-L1 pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:58:28.303Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, PD-L1 positive"},{"name":"Metastatic melanoma"}]},"trialDetails":[{"nctId":"NCT02864901","phase":"PHASE2","title":"Is an Antiplaque Chewing Gum (30 mg) Able to Reduce Dental Plaque in a Healthy Population?","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2016-10","conditions":"Plaque Regrowth","enrollment":27},{"nctId":"NCT01877421","phase":"PHASE1, PHASE2","title":"Safety and Tolerability of Antiplaque Chewing Gum in a Gingivitis Population","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2014-02-25","conditions":"Plaque, Gingivitis","enrollment":135}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":25,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Antimicrobial decapeptide KSL-W"],"phase":"phase_2","status":"active","brandName":"KSL-W","genericName":"KSL-W","companyName":"U.S. Army Medical Research and Development Command","companyId":"u-s-army-medical-research-and-development-command","modality":"Small molecule","firstApprovalDate":"","aiSummary":"KSL-W is a small molecule drug that targets the PD-1/PD-L1 pathway. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic melanoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}